Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO/COO Nelson Sun eligible for $346,500 retention payment on January 1, 2027.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO/COO Nelson Sun eligible for $346,500 retention payment on January 1, 2027
- CMO Manasi Jaiman eligible for $357,000 retention payment on January 1, 2027
- Combined potential cash obligation of $703,500 tied to continued employment through January 1, 2027
- Termination without Cause or resignation for Good Reason accelerates payment, subject to claims release
- Agreements signal retention priority for key finance, operations, and clinical leadership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.